Bioporto: Wrap up from Q3 event
Bioporto: Wrap up from Q3 event with CEO Tony Pare and VP Controlling and Reporting George Rosa.
CEO Tony Pare gave an in depth explanation of The FDA process and the 510K application. When NGAL is approved by FDA, what will happen with reimbursement? Bioporto partner in US is Roche.
NGAL sales increased 20% in Q3 on a YoY comparison.
CEO Tony Pare mentioned the following priorities going forward - Gain FDA approval, expand TAM in the US and grow the business in ROW.
Listen to full interview here: Q3 event
Disclaimer: HC Andersen Capital receives payment from Bioporto for a Digital IR/Corporate Visibility subscription agreement. /Claus Thestrup 1:00 PM 02-11-2023.
Login required
This content is only available for logged in users
